Medimap Logo

Are there any newer molecules for dyspepsia that do not pose long-term risks?

There are currently no newer molecules for dyspepsia that do not carry long-term risks. Proton pump inhibitors (PPIs) are still the first-line treatment for conditions such as esophagitis, ulcers, and reflux. It is recommended to periodically monitor therapy due to potential risks associated with their use.
Are there any newer molecules for dyspepsia that do not pose long-term risks? - Medimap.ca